Restricted accessResearch articleFirst published online 2012-1
The Changes in Plasma Retinol-Binding Protein 4 Levels are Associated With Those of the Apolipoprotein B-Containing Lipoproteins During Dietary and Drug Treatment
We investigated the association between retinol-binding protein 4 (RBP4) and apolipoprotein B (ApoB)-containing lipoproteins. Obese or overweight, hypertriglyceridemic patients underwent the following interventions for 3 months: (1) Diet (n = 20), (2) Diet + fenofibrate (n = 18), (3) Diet + rimonabant (n = 8). Circulating RBP4 decreased during dietary treatment. The percentage change in RBP4 was positively correlated with the percentage changes in very-low density lipoprotein cholesterol (r = .570, P = .02), low-density lipoprotein cholesterol ([LDL-C]; r = .605, P = .01), ApoB (r = .705, P = .007), and small dense LDL-C ([sdLDL-C]; r = .872, P < .001). The percentage change in RBP4 was the best predictor of the percentage changes in sdLDL-C and ApoB. Rimonabant treatment reduced RBP4, whereas fenofibrate increased RBP4 during the first month of therapy followed by a subsequent decrease. In conclusion, RBP4 may significantly influence the metabolic pathways responsible for changes in ApoB lipoprotein subspecies, thus RBP4 may be associated with cardiovascular disease risk.
BlanerWS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev. 1989;10(3):308–316.
2.
YangQGrahamTEModyN. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049):356–362.
3.
GrahamTEYangQBluherM. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med. 2006;354(24):2552–2563.
4.
IngelssonESundstromJMelhusH. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009;206(1):38–39.
5.
KlotingNGrahamTEBerndtJ. Serum Retinol-Binding Protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007;6(1):79–87.
6.
JiaWWuHBaoY. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrine Metab. 2007;92(8):3224–3229.
7.
YuanGAl-ShaliKZHegeleRA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–1120.
8.
BerneisKKKraussRM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–1379.
9.
FlorentinMTselepisADElisafMSRizosCVMikhailidisDPLiberopoulosEN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010;8(6):820–830.
10.
CabreALazaroIGironaJ. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease. J Intern Med. 2007;262(4):496–503.
11.
MallatZSimonTBenessianoJ. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009;94(1):255–260.
12.
IngelssonELindL. Circulating retinol binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care. 2009;32(4):733–735.
13.
SoliniASantiniEMadecSRossiCMuscelliE. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens. 2009;22(9):1001–1006.
14.
ParkSEKimDHLeeJH. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis. 2009;204(1):23–25.
15.
UsuiSIchimuraMIkedaSOkamotoM. Association between serum retinol-binding protein 4 and small dense low-density lipoprotein cholesterol levels in young adult women. Clinica Chimica Acta. 2009;399(1-2):45–48.
16.
National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
17.
GaziILouridaESFilippatosTTsimihodimosVElisafMTselepisAD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51(12):2264–2273.
18.
FlorentinMLiberopoulosENFilippatosTD. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother. 2008;9(16):2741–2750.
19.
EvangelouPTzotzasTChristouGElisafMSKiortsisDN. Does the presence of metabolic syndome influence weight loss in obese and overweight women?. Metab Syndr Relat Disord. 2010;8(2):173–178.
20.
StefanNHennigeAMStaigerH. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007;30(5):1173–1178.
21.
NgTWWattsGFBarrettPHRyeKAChanDC. Effect of weight loss on LDL and HDL kinetics in the Metabolic Syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007;30(11):2945–2950.
22.
BalagopalPGrahamTEKahnBBAltomareAFunanageVGeorgeD. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007;92(5):1971–1974.
23.
ReinehrTStoffel-WagnerBRothCL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(6):2287–2293.
24.
VolekJSPhinneySDForsytheCE. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44(4):297–309.
25.
HermsdorffHHZuletMÁAbeteIMartínezJA. Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine. 2009;36(3):445–451.
26.
KiortsisDNTzotzasTGiralP. Changes in lipoprotein (a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis. 2001;11(3):153–157.
27.
FriedewaldWTLevyRIFredericksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
28.
Von EyattenMLepperPMLiuD. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007;50(9):1930–1937.
29.
ChristensenEIMoskaugJOVorumH. Evidence for an essential role of megalin in transepithelial transport of retinol. J Am Soc Nephrol. 1999;10(4):685–695.
30.
RailaJWillnowTESchweigertFJ. Megalin-mediated reuptake of retinol in the kidneys of mice is essential for vitamin A homeostasis. J Nutr. 2005;135(11):2512–2516.
31.
PiscatorM. Early detection of tubular dysfunction. Kidney Int Suppl. 1991;34:S15–S17.
32.
SmithFRGoodmanDS. The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. J Clin Invest. 1971;50(11):2426–2436.
33.
VahlquistAPetersonPAWibellL. Metabolism of the vitamin A transporting protein complex. I. Turnover studies in normal persons and in patients with chronic renal failure. Eur J Clin Invest. 1973;3(4):352–362.
34.
ZiegelmeierMBachmannASeegerJ. Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care. 2007;30(10):2588–2592.
35.
ChangYHLinKDWangCLHsiehMCHsiaoPJShinSJ. Elevated serum retinol-binding protein 4 concentrations are associated with renal dysfunction and uric acid in type 2 diabetic patients. Diabetes Metab Res Rev. 2008;24(8):629–634.
36.
KeechASimesRJBarterP. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
37.
WuHWeiLBaoY. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. Am J Physiol Endocrinol Metab. 2009;296(4):628–634.
38.
MohapatraJSharmaMSinghS. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. J Pharm Pharmacol. 2009;61(11):1493–1498.
39.
Van GaalLFRissanenAMScheenAJZieglerORössnerSRIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–1397.
